Cocrystal Pharma, Inc. (COCP) Financial Analysis & Valuation | Quarter Chart
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coro... more
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antivir... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $15.79M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | James E. Sapirstein |
| IPO Date | 2012-02-22 | CAGR | — |
| Employees | 10 | Website | www.cocrystalpharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
COCP chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $14.27M | P/E | -1.51 | Forward P/E | -1.97 | PEG | — |
| P/S | 228.08 | P/B | 72.05 | P/CF | -9.23 | P/FCF | -9.23 |
| Sales | $330,000 | Sales 1Y | inf% | Sales 3Y | inf% | Sales 5Y | -66.97% |
| EPS | $-0.76 | EPS 1Y | -37.9% | EPS 3Y | -66.67% | EPS 5Y | -58.6% |
| Sales QoQ | -53.33% | EPS QoQ | 35.29% | Sales QoQ Avg | — | EPS QoQ Avg | 4.87% |
| Gross Margin | 205.76% | Operating Margin | -3063.64% | Profit Margin | -3011.52% | ROCE | -497.29% |
| ROA | -214% | ROE | -207% | Altman Z Score | -101.79 | Piotroski Score | 3 |
| Current Ratio | 1.24 | Quick Ratio | 1.24 | Cash Ratio | 0.83 | Op. CF Ratio | -0.96 |
| Debt/Equity | 1.28 | Debt/Assets | 0.29 | Lt Debt/Equity | 0.95 | Lt Debt/Cap. | 0.49 |
| Intrst Cov. | — | Inventory Turnover | — | Asset Turnover | 0.07 | Receivables Turnover | — |
| Enterprise Value | $14.27M | P/E Ratio | -1.51 |
| Forward P/E | -1.97 | PEG Ratio | — |
| P/S Ratio | 228.08 | P/B Ratio | 72.05 |
| P/CF Ratio | -9.23 | P/FCF Ratio | -9.23 |
| EPS | $-0.76 | EPS Growth 1Y | -37.9% |
| EPS Growth 3Y | -66.67% | EPS Growth 5Y | -58.6% |
| Revenue Growth 1Y | inf% | Gross Margin | 205.76% |
| Operating Margin | -3063.64% | Profit Margin | -3011.52% |
| ROE | -207% | ROA | -214% |
| ROCE | -497.29% | Current Ratio | 1.24 |
| Quick Ratio | 1.24 | Cash Ratio | 0.83 |
| Debt/Equity | 1.28 | Interest Coverage | — |
| Altman Z Score | -101.79 | Piotroski Score | 3 |
Cocrystal Pharma, Inc. (COCP) valuation & financials
Cocrystal Pharma, Inc. (COCP) has a market capitalization of $15.79M and trades at a price-to-earnings ratio of -1.5. It operates in the Healthcare sector (Biotechnology).
Cocrystal Pharma, Inc.'s revenue grew — over the last year.
Cocrystal Pharma, Inc.'s next earnings report is scheduled for November 13, 2026 before market open (provider scheduled date); analysts estimate EPS of $-0.15. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)